Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice

Jehad H. Edwan, James E. Talmadge, Devendra K. Agrawal

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P

Original languageEnglish
Pages (from-to)345-357
Number of pages13
JournalInternational Immunopharmacology
Volume5
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Ovalbumin
Plasmids
Inflammation
Methacholine Chloride
Intramuscular Injections
Bronchoalveolar Lavage Fluid
Therapeutics
Immunoglobulins
Asthma
Cytokines
flt3 ligand protein
Serum

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology

Cite this

Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice. / Edwan, Jehad H.; Talmadge, James E.; Agrawal, Devendra K.

In: International Immunopharmacology, Vol. 5, No. 2, 02.2005, p. 345-357.

Research output: Contribution to journalArticle

@article{a671013f39d94914b22de188f61b214c,
title = "Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice",
abstract = "We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P",
author = "Edwan, {Jehad H.} and Talmadge, {James E.} and Agrawal, {Devendra K.}",
year = "2005",
month = "2",
doi = "10.1016/j.intimp.2004.10.002",
language = "English",
volume = "5",
pages = "345--357",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice

AU - Edwan, Jehad H.

AU - Talmadge, James E.

AU - Agrawal, Devendra K.

PY - 2005/2

Y1 - 2005/2

N2 - We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P

AB - We have previously reported that fms-like tyrosine kinase 3 ligand (Flt3-L) prevents and reverses established allergic airway inflammation in an ovalbumin (OVA) induced mouse model of asthma. In this study, we investigated the effect of pUMVC3-hFLex, a plasmid, mammalian expression vector for the secretion of Flt3-L on the same mouse model as well as the duration of the effect of the treatment. Allergic airway inflammation to OVA was established in BALB/c mice. OVA-sensitized mice received three intramuscular (i.m.) injections of 200 μg pUMVC3-hFLex over 10 days. The response to pUMVC3-hFLex therapy was assessed based on airway hyperresponsiveness (AHR) to methacholine and inflammation, measured as serum cytokine and immunoglobulins (Ig) levels, and the total and differential cells in bronchoalveolar lavage fluid (BALF). pUMVC3-hFLex treatment completely reversed established AHR (P

UR - http://www.scopus.com/inward/record.url?scp=12344298548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344298548&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2004.10.002

DO - 10.1016/j.intimp.2004.10.002

M3 - Article

C2 - 15652764

AN - SCOPUS:12344298548

VL - 5

SP - 345

EP - 357

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -